FDA Issues Emergency Use Authorization for Over-the-Counter Injectable Drug for New World Screwworm in Dairy Cattle, Horses, Swine, Sheep, and Deer

The U.S. Food and Drug Administration issued an EUA that also authorizes Dectomax/Dectomax-CA1 for the prevention of NWS myiasis in swine, horses at least one year old, sheep except for lactating sheep, and deer.

It is reasonable to believe that Dectomax/Dectomax-CA1 may be effective for the indications in the species described above, and the known and potential benefits of the product outweigh its known and potential risks.

According to Towards Healthcare, the North America animal health market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 85.26 billion in 2026 to approximately USD 176.5 billion by 2035, representing a compound annual growth rate (CAGR) of 8.42% from 2026 to 2035. Growth is driven by R&D, which has shifted significantly toward preventive veterinary care, such as advanced parasiticides and vaccines. In livestock, the push for organic and sustainable meat production is driving the use of natural alternatives to antibiotics, such as probiotics and phage therapy.

About Dectomax and Dectomax-CA1

Dectomax and Dectomax-CA1 are broad-spectrum veterinary parasiticides containing doramectin, an antiparasitic drug. They are used to treat and prevent internal and external parasites in livestock, including gastrointestinal roundworms, lungworms, sucking lice, and mange mites.

Dectomax-CA1 is a conditionally approved formulation specifically indicated for the prevention and treatment of infestations caused by the New World Screwworm (NWS) (Cochliomyia hominivorax). It provides up to 21 days of prevention against reinfestation. Under the FDA Emergency Use Authorization (EUA), its usage has been expanded to manage NWS risks in specific scenarios.

The FDA has concluded that, based on the totality of the scientific evidence available, it is reasonable to believe that Dectomax/Dectomax-CA1 may be effective for the indications in the species described above, and the known and potential benefits of the product outweigh its known and potential risks.

There is a booming market for precision medicine, IoT-enabled health monitors, and AI-powered diagnostic tools designed to catch diseases early.

A recent report by Towards Healthcare highlights that the North America animal health market is witnessing growth driven by the shift away from reactive, treatment-only care, which has created a high-margin opportunity for early diagnostic screenings and preventative therapeutics. As animal populations rise, veterinary clinics are heavily investing in geriatric care and specialized nutrition. It enforces a new era of harmonised welfare standards for companion animals across Europe.This robust opportunity is primarily driven by rising pet humanization, increased preventative care, and a strong regional veterinary infrastructure.